IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Subscribe To Our Newsletter & Stay Updated